United States Infectious Disease Therapeutics Market Size, Share, and COVID-19 Impact Analysis, By Infection Type (Parasitic Infection, Bacterial Infection, Fungal Infection, and Viral Infection), By Drug Class (Antiparasitic, Vaccines, Antibiotics, Immunotherapies, Antivirals, and Antifungals), By Route of Administration (Parenteral, Oral, and Intranasal), By Distribution Channel (Retail Pharmacies, Online Pharmacies, and Hospital Pharmacies), and US Infectious Disease Therapeutics Market Insights, Industry Trend, Forecasts to 2035

USA Infectious Disease Therapeutics Market Insights Forecasts to 2035

• The US Infectious Disease Therapeutics Market Size was Estimated at USD 81.62 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 2.44% from 2025 to 2035
• The USA Infectious Disease Therapeutics Market Size is Expected to reach USD 106.46 Billion by 2035

According to a research report published by Spherical Insights & Consulting, the US Infectious Disease Therapeutics Market Size is anticipated to reach USD 106.46 Billion by 2035, Growing at a CAGR of 2.44% from 2025 to 2035. The market growth is attributed to the growing prevalence of infectious diseases among the United States population, exposure to unhygienic places, and innovations in the drug discovery process and therapeutics.

Market Overview

The United States infectious disease therapeutics market includes the development, production, and commercialization of the medications used for the management of infectious diseases, such as bacterial, viral, and fungal. Infectious diseases are conditions caused by tiny organisms, such as bacteria, viruses, fungi, or parasites, that can spread from person to person either directly or indirectly. They are a major cause of death in the USA, particularly for young children and in low-income nations. Microbes or microorganisms are common terms used to describe pathogenic organisms, including bacteria, viruses, protozoa, and fungi. An infectious disease is a condition caused by a virus or its toxic byproduct that spreads to a vulnerable host from an infected human, animal, or contaminated inanimate object. The drugs that cure and treat infectious diseases are known as infectious disease therapeutics. Antibiotics are used to treat bacterial infections by killing or preventing their spread, such as penicillin. Antivirals inhibit the production of viruses, preventing their replication or blocking their entry into host cells. Antifungals treat fungal infections by inhibiting fungal membrane and cell wall synthesis, altering fungal membranes, affecting microtubules, and inhibiting nucleic acid synthesis. Antiparasitic drugs are used to manage and treat infections by parasites, including protozoa, helminths, and ectoparasites, such as ivermectin and albendazole. The development of monoclonal antibodies, vaccines, antibiotics, and antiviral medications is causing major changes in the infectious disease treatment sector. In order to fight antimicrobial resistance, pharmaceutical companies are concentrating on creating combination therapies, improving bioavailability, and better medication formulations, which drives the market growth. Rapid technical breakthroughs, greater research and development, and the growing need for innovative treatment modalities have all contributed to governments and healthcare organizations making significant investments in therapeutic solutions in response to the growth in infectious diseases, both communicable and non-communicable.

Report Coverage

This research report categorizes the market for the US infectious disease therapeutics market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the US infectious disease therapeutics market. Recent market developments and competitive strategies such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the US infectious disease therapeutics market.

Driving Factors

Growing prevalence of the chronic disease:

The infectious disease therapeutics market is experiencing growth due to the increasing prevalence of infectious diseases, urbanization, climate change, and global travel. The resurgence of TB and antimicrobial resistance are major concerns driving market expansion. Chronic viral infections like HIV and hepatitis also expand the market for antiviral drugs. The need for improved therapies to manage and treat these diseases is constant. The spread of vector-borne diseases like malaria, exacerbated by climate change, also contributes to market growth. Overall, the increasing prevalence of infectious diseases is driving market growth.

Innovations and development in the medical sector:

The market for infectious disease therapeutics has grown dramatically as a result of developments in medical research and technology. More precise and efficient treatments for a range of illnesses have been made possible by advancements in biotechnology, genetics, and drug development. Early identification and treatment outcomes have improved as a result of a better understanding of pathogen genetic makeup. In order to combat antimicrobial resistance, new drug development techniques, including structure-based design and high-throughput screening, have sped up the identification of new antibiotics and antivirals. Furthermore, advancements in drug delivery technologies, like targeted technologies and extended-release formulations, improve the safety and effectiveness of treatment.

Restraining Factors

The high cost of the antibiotics, stringent regulatory challenges, limited access to healthcare in low-income countries, side effects associated with repeated use of drugs, and antimicrobial resistance may impede the market growth.

Market Segmentation

The USA infectious disease therapeutics market share is classified into infection type, drug class, route of administration, and distribution channel.

• The bacterial infection segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The US infectious disease therapeutics market is segmented by infection type into parasitic infection, bacterial infection, fungal infection, and viral infection. Among these, the bacterial infection segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period. The rising prevalence of urinary tract infection, pneumonia, tuberculosis, and syphilis drives the segmental expansion.

• The antibiotics segment accounted for the largest share in 2024 and is predicted to grow at a significant CAGR during the forecast period.

The US infectious disease therapeutics market is segmented by drug class into antiparasitic, vaccines, antibiotics, immunotherapies, antivirals, and antifungals. Among these, the antibiotics segment accounted for the largest share in 2024 and is predicted to grow at a significant CAGR during the forecast period. The segment growth is driven by the increasing cases of bacterial infections, growing use of antibiotics as over-the-counter medications, efficacy of the antibiotics, and effective treatment for bacterial diseases.

• The oral segment dominated the United States infectious disease therapeutics market in 2024 and is expected to grow at a significant CAGR during the forecast period.

The US infectious disease therapeutics market is segmented by route of administration into parenteral, oral, and intranasal. Among these, the oral segment dominated the United States infectious disease therapeutics market in 2024 and is expected to grow at a significant CAGR during the forecast period. The segmental dominance is attributed to the following factors, such as being suitable for the pediatric and geriatric population, cost effectiveness, patient compliance, ease of administration, patient compliance, and availability of the novel drug delivery system for oral medications.

• The hospital pharmacies segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

The US infectious disease therapeutics market is segmented by distribution channel into retail pharmacies, online pharmacies, and hospital pharmacies. Among these, the hospital pharmacies segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The sectoral growth is ascribed to the availability of the provision of the compounding and dispensing medications, offers discount on the purchase of medications, collaboration of the hospital and hospital pharmacies improve the patient health outcomes, and availability of the wide range of the medication used for the management of the infectious disease and other disease.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the US infectious disease therapeutics market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Sandoz Iternational GmbH
• Mankind Pharma
• AstraZeneca
• Novartis AG
• Gilead Science, Inc.
• B. Braun SE
• AbbVie.
• Bayer AG
• Bristol-Myers Squibb
• Others

Recent Developments:

• In May 2025, Avenacy, a specialty pharmaceutical company, launched Doxycycline for Injection, USP in the US as a therapeutic generic equivalent for DOXY 100®, approved by the FDA. This broad-spectrum antibiotic is used to treat infections caused by susceptible bacteria, including certain strains of gram-negative and gram-positive organisms, rickettsiae, and spirochetes, and is also used as an alternative for patients with penicillin allergies.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the United States, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the US infectious disease therapeutics market based on the below-mentioned segments:

US Infectious Disease Therapeutics Market, By Infection Type

• Parasitic Infection
• Bacterial Infection
• Fungal Infection
• Viral Infection

US Infectious Disease Therapeutics Market, By Drug Class

• Antiparasitic
• Vaccines
• Antibiotics
• Immunotherapies
• Antivirals
• Antifungals

US Infectious Disease Therapeutics Market, By Route of Administration

• Parenteral
• Oral
• Intranasal

US Infectious Disease Therapeutics Market, By Distribution Channel

• Retail Pharmacies
• Online Pharmacies
• Hospital Pharmacies